21 C.F.R. § 522.224

Bupivacaine.

Last amended: 2020Year: 2026Length: 138 wordsSubsections: 3Official source

Cite as 21 C.F.R. § 522.224 (2026)

(a) Specifications. Each milliliter (mL) of liposomal suspension contains 13.3 milligrams (mg) bupivacaine. (b) Sponsor. See No. 058198 in § 510.600(c) of this chapter. (c) Conditions of use —(1) Dogs —(i) Amount. Administer 5.3 mg/kg (0.4 mL/kg) by infiltration injection into the tissue layers at the time of incisional closure. (ii) Indications for use. For single-dose infiltration into the surgical site to provide local postoperative analgesia for cranial cruciate ligament surgery. (2) Cats —(i) Amount. Administer 5.3 mg/kg per forelimb (0.4 mL/kg per forelimb), for a total dose of 10.6 mg/kg/cat, as a 4-point nerve block prior to onychectomy. (ii) Indications for use. For use as a peripheral nerve block to provide regional postoperative analgesia following onychectomy. [81 FR 67151, Sept. 30, 2016, as amended at 84 FR 8973, Mar. 13, 2019; 85 FR 4208, Jan. 24, 2020]
Cross-references to the CFR
510.600
21 C.F.R. § 522.224: Bupivacaine. | Justis AI